|Bid||1.4000 x 1200|
|Ask||1.9300 x 800|
|Day's Range||1.7000 - 1.8000|
|52 Week Range||1.0000 - 2.9200|
|Beta (3Y Monthly)||2.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.75|
Karyopharm's (KPTI) stock rises despite the FDA's decision to delay the verdict on the NDA filing of selinexor, which is developed for treating patients with relapsed-refractory multiple myeloma.
Spectrum Pharma (SPPI) withdraws the BLA seeking approval for Rolontis, as the FDA requests for additional manufacturing-related data.
Shares of Infinity (INFI) rise after the company inks deal with Roche to initiate a phase II MARIO-3 study on IPI-549. Per the deal, Roche will supply Tecentriq (atezolizumab) to Infinity.
Infinity (INFI) delivered earnings and revenue surprises of 17.65% and 192.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cambridge, Massachusetts-based company said it had a loss of 14 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
-- Copiktra™ Royalty Monetization for $30M in Gross Proceeds -- -- Roche/Genentech Clinical Collaboration on MARIO-3 in Front-Line Triple Negative Breast Cancer and Renal Cell Cancer -- -- BMS Clinical ...
- Infinity Enters into Master Clinical Supply Agreement with Roche to Provide atezolizumab (Tecentriq®) for MARIO-3 - - MARIO-3 Will Evaluate IPI-549 with Tecentriq and Abraxane® in Front-Line Triple Negative ...
NEW YORK, NY / ACCESSWIRE / March 14, 2019 / Infinity Pharmaceuticals, Inc. (NASDAQ: INFI ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 14, 2019, ...
CAMBRIDGE, Mass. , March 7, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Thursday, March 14, 2019 , at 8:00 a.m. ET to review its full year 2018 financial ...
CAMBRIDGE, Mass., March 6, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (INFI) announced today a royalty monetization with HealthCare Royalty Partners (HCR) for the right to receive certain royalty payments based on worldwide annual net sales of COPIKTRA™ (duvelisib), payable by Verastem. Under the agreement, HCR has agreed to pay Infinity a $30 million upfront payment and up to $20 million in potential milestone payments. The right to receive royalty payments will revert to Infinity if HCR receives a multiple of its total investment amount and certain reasonably incurred expenses paid by HCR, up to a prespecified cap amount which increases over time.
NEW YORK, Feb. 06, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
CAMBRIDGE, Mass. , Feb. 4, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that Adelene Perkins , Infinity Pharmaceutical's Chief Executive Officer, will present at the ...
-IPI-549 Safety and Clinical Activity Support Initiation of Studies in Earlier Lines of Cancer Therapy with Double and Triple Combination Regimens- -MARIO-275:Global, Randomized Study of IPI-549 and Opdivo ...
CAMBRIDGE, Mass. , Jan. 3, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the 37 th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 , at ...
Infinity (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inc. were in the green after announcing the company will be acquired for $5.7 billion in cash by Veritas Capital and Evergreen Coast Capital. Infinity Pharmaceuticals, Inc. shares closed down 45.42% on about 4.6 million shares traded yesterday. "Today's data validate our scientific rationale for the development of IPI-549 as a potentially first-in-class therapeutic alternative for patients lacking better treatment options," said Adelene Perkins, Chief Executive Officer of Infinity Pharmaceuticals.
CAMBRIDGE, Mass., Nov. 10, 2018 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (INFI) announced that data to be presented today at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) demonstrated preliminary evidence that IPI-549 in combination with Opdivo® (nivolumab) is clinically active in indications not expected to respond to Opdivo alone. In particular, evidence of reversal of resistance to Opdivo included a partial response in a patient with metastatic melanoma who progressed on immediate prior Opdivo therapy.
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Bristol-Myers (BMY) signs a contract with Infinity Pharmaceuticals to evaluate the combination of its Pd-1 inhibitor Opdivo and Infinity's IPI-549 for treating advanced urothelial cancer
Infinity (INFI) beats earnings estimates in the third quarter of 2018. The company revised its outlook for 2018 and expects net loss for 2018 to be $10-$20 million, down from its previous expectation of $35-$45 million.
On a per-share basis, the Cambridge, Massachusetts-based company said it had net income of 23 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
- Plans to Initiate IPI-549 MARIO-275, a Randomized, Global Phase 2 Study in Urothelial Cancer in Clinical Collaboration with Bristol-Myers Squibb - - Late-Breaking Presentation at the Society for Immunotherapy ...
-- Plans to Initiate MARIO-275, a Randomized, Global Phase 2 Study in 1H’19--